UCM in the AFR, page-184

Diamondstock: To answer your question ...
"gentleman answer me this,company introduced the USCOM 1A more than 10 years ago.why hasn't it taken off already? why would it decide to take off now rather than then?"

Ah! but it has - you need to view the bigger picture!
The USCOM 1A is where it is today - in a unique position with a very wide moat that is unlikely to be paralleled or duplicated because it is at the end of a 20+ year journey and about to blossom.
THE TIMELINE goes something like this:
By Year 2000 - the concept of the Uscom 1a had been invented, prototyped and proven by Associate Professor Rob Phillips at the University of Queensland. Rob saw its potential and resolved to take it to the world.

Year 2000 - Company USCOM formed to develop and commercialize the device.

Years 2000-2006: development - field testing and final release in 2006 of a reliable commercial product. Setting up a manufacturing base in Sydney. The USCOM 1A was an innovative, practice changing non-invasive cardiovascular and pulmonary monitoring device - that was launched on a medical world who believed you needed to insert a Catheter into an artery to measure blood flow - this was the considered Gold Standard at the time - promoted and supported by powerful corporate vested interests.

2006 to 2012 USCOM (the Disruptor) had to demonstrate and prove its science to a conservative medical world. Rob Phillips traveled the world: demonstrating, educating, and building a powerful following among medical innovators. In time the tables were turned and the 1A BECAME THE NEW GOLD STANDARD.

2013-2016 USCOM Directors understanding they had developed the core of an aggressive global growth strategy and seeking to expand and develop their product range acquired companion practice changing and complimentary non-invasive cardiovascular and pulmonary technologies. Uscom acquired Pulsecor Limited in 2013, and Thor Laboratories in 2015. By 2016 they had a company structure and manufacturing base in both Sydney and the European Union.

2016-2018 Uscom developed and launched the BP+ and BP+ Reporter, and SpiroSonic digital ultrasonic spirometer series and the proprietary SpiroReporter software. These devices began changing the way cardiovascular and pulmonary medicine is practiced. The BP+ is currently in use on board the International Space Station for critical monitoring of brachial BP and cBP in astronauts.

By around this time there were over 1000 USCOM 1A units in use by progressive medical institutions around the world - which have already helped enhance hundreds of thousands of lives.

2018-2020 USCOM identified China as a major future market and resolved to open and staff a China Office. It is fortuitous that this office was up and running fully staffed at the time of the Covid-19 virus outbreak.

Effective and extensive patent protection underwrites the development and commercialization of all Uscom products, and the future commercial opportunities for Uscom.

So @Diamondstock it has been a long journey of forward planning, growth, continual reinvestment - in which this innovative, ethical and well run Australian company has over the last 20 years quietly established itself as a niche leader in a world market.
For some of us this is also an ethical investment that has already done a lot of good and made a difference to a lot of people and there are lots of stories and videos on the net, if you wish to look.

I guess USCOM is one of the better kept secrets on the ASX but it is a rock solid organisation with a very bright future very well led by the founder and Executive Chairman of 20 years Rob Phillips. Uscom has no debt.
"Blind Fredie" can see the company is undervalued at the current share price and I suspect most shareholders believe it is about to enter a major cashflow positive growth phase. This is a stock for the buy and hold brigade!.